Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | GJA1 | P17302 | 1/20 | 0.44 |
| ▸ | GJB2 | P29033 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | IGF2R | P11717 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12846337 | 0.82 | MEN1 (0.74) | MEN1KMT2AGJA1GJB2CYP2C9 | |
| SCHEMBL30565141 | 0.82 | MEN1 (0.58) | MEN1KMT2AGJA1GJB2CYP2C9 | |
| SCHEMBL29832355 | 0.82 | MEN1 (0.64) | MEN1KMT2AGJA1GJB2CYP2C9 | |
| Lactulose SCHEMBL180915 | 0.80 | MEN1 (1.00) | MEN1KMT2AGJA1GJB2CYP2C9 | |
| Lactulose SCHEMBL11892653 | 0.80 | MEN1 (1.00) | MEN1KMT2AGJA1GJB2CYP2C9 | |
| Lactulose SCHEMBL18470690 | 0.80 | MEN1 (1.00) | MEN1KMT2AGJA1GJB2CYP2C9 | |
| Lactulose SCHEMBL15942980 | 0.80 | MEN1 (1.00) | MEN1KMT2AGJA1GJB2CYP2C9 | |
| Lactulose SCHEMBL12787176 | 0.80 | MEN1 (1.00) | MEN1KMT2AGJA1GJB2CYP2C9 | |
| Lactulose SCHEMBL17241809 | 0.80 | MEN1 (1.00) | MEN1KMT2AGJA1GJB2CYP2C9 | |
| Lactulose SCHEMBL18479188 | 0.80 | MEN1 (1.00) | MEN1KMT2AGJA1GJB2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897763-B1 | HYDROGEL COMPOSITIONS ENCAPSULATING SOLID PARTICLES | Galderma Holding SA (CH) | 2025-04-09 | — | — | EP | claimed |
| EP-4279537-B1 | CARBOHYDRATE CROSSLINKER | Galderma Holding SA (CH) | 2026-02-04 | — | — | EP | disclosed |
| US-20250197531-A1 | COMPOSITION, IN THE FORM OF AN AQUEOUS SOLUTION COMPRISING AT LEAST ONE MACROMOLECULAR COMPOUND | LABORATOIRES VIVACY (FR) | 2025-06-19 | — | — | US | disclosed |
| EP-4426751-A1 | COMPOSITION, IN THE FORM OF AN AQUEOUS SOLUTION COMPRISING AT LEAST ONE MACROMOLECULAR COMPOUND | Laboratoires Vivacy (FR) | 2024-09-11 | — | — | EP | disclosed |
| US-11780970-B2 | Carbohydrate crosslinker | GALDERMA HOLDING S.A. (CH) | 2023-10-10 | — | — | US | disclosed |
| EP-3623390-B1 | CARBOHYDRATE CROSSLINKER | GALDERMA SA (CH) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023079154-A1 | COMPOSITION, IN THE FORM OF AN AQUEOUS SOLUTION COMPRISING AT LEAST ONE MACROMOLECULAR COMPOUND | LABORATOIRES VIVACY (FR) | 2023-05-11 | — | — | WO | disclosed |
| EP-4177276-A1 | COMPOSITION, IN THE FORM OF AQUEOUS SOLUTION COMPRISING AT LEAST ONE MACROMOLECULAR COMPOUND | Laboratoires Vivacy (FR) | 2023-05-10 | — | — | EP | disclosed |
| CN-115335414-A | High molecular weight cosmetic compositions | 高德美控股有限公司 | 2022-11-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780970-B2 | Carbohydrate crosslinker | CD44, CSGALNACT1, STT3B | MEN1 3187/4885KMT2A 3411/4885GJA1 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.